NCT06151730View on ClinicalTrials.gov

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Chronic Lymphocytic LeukemiaHematopoietic and Lymphoid System NeoplasmMantle Cell LymphomaMarginal Zone LymphomaWaldenstrom Macroglobulinemia
Interventions
OTHER

Non-Interventional Study

Non-interventional study

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06151730 - Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study | Biotech Hunter | Biotech Hunter